Overexpression of Heme Oxygenase-1 Protects Dopaminergic Neurons against 1-Methyl-4-Phenylpyridinium-Induced Neurotoxicity

Heme oxygenase-1 (HO-1) is up-regulated in response to oxidative stress and catalyzes the degradation of pro-oxidant heme to carbon monoxide (CO), iron, and bilirubin. Intense HO-1 immunostaining in the Parkinsonian brain is demonstrated, indicating that HO-1 may be involved in the pathogenesis of Parkinsonism. We here locally injected adenovirus containing human HO-1 gene (Ad-HO-1) into rat substantia nigra concomitantly with 1-methyl-4-phenylpyridinium (MPP+). Seven days after injection of MPP+ and Ad-HO-1, the brain was isolated for immunostaining and for measurement of dopamine content and inflammatory cytokines. It was found that overexpression of HO-1 significantly increased the survival rate of dopaminergic neurons; reduced the production of tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) in substantia nigra; antagonized the reduction of striatal dopamine content induced by MPP+; and also up-regulated brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) expression in substantia nigra. Apomorphine-induced rotation after MPP+ treatment was also inhibited by Ad-HO-1. On the other hand, inhibition of HO enzymatic activity by zinc protoporphyrin-IX facilitated the MPP+-induced rotatory behavior and enhanced the reduction of dopamine content. HO-1 overexpression also protected dopaminergic neurons against MPP+-induced neurotoxicity in midbrain neuron-glia cocultures. Overexpression of HO-1 increased the expression of BDNF and GDNF in astrocytes and BDNF in neurons. Our results indicate that HO-1 induction exerts neuroprotection both in vitro and in vivo. Pharmacological or genetic approaches targeting HO-1 may represent a promising and novel therapeutic strategy in treating Parkinsonism.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  P. Gean,et al.  Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes , 2006, Molecular Psychiatry.

[3]  K. Mohanakumar,et al.  Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine , 2006, Pharmacology Biochemistry and Behavior.

[4]  Jawed Alam,et al.  Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. , 2006, Physiological reviews.

[5]  R. Regan,et al.  Cultured astrocytes from heme oxygenase‐1 knockout mice are more vulnerable to heme‐mediated oxidative injury , 2005, Journal of neuroscience research.

[6]  D. Brooks,et al.  Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain , 2005, Nature Medicine.

[7]  L. Garey,et al.  Heme oxygenase‐1 activity after excitotoxic injury: Immunohistochemical localization of bilirubin in neurons and astrocytes and deleterious effects of heme oxygenase inhibition on neuronal survival after kainate treatment , 2005, Journal of neuroscience research.

[8]  J. Parga,et al.  Glial overexpression of heme oxygenase-1: a histochemical marker for early stages of striatal damage , 2005, Journal of Chemical Neuroanatomy.

[9]  S. Gill,et al.  Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.

[10]  H. Schipper.  Heme oxygenase expression in human central nervous system disorders. , 2004, Free radical biology & medicine.

[11]  J. Chen,et al.  Adenoviral transfer of the heme oxygenase-1 gene protects striatal astrocytes from heme-mediated oxidative injury , 2004, Neurobiology of Disease.

[12]  A. Ludolph,et al.  Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration , 2004, Journal of Neural Transmission.

[13]  S. Ryter,et al.  The FASEB Journal • Research Communication Caveolae compartmentalization of heme oxygenase-1 in endothelial cells , 2022 .

[14]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[15]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[16]  N. Bodyak,et al.  Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury , 2003, Nature Medicine.

[17]  Solomon H. Snyder,et al.  Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Sarathchandra,et al.  Carbon Monoxide-Releasing Molecules: Characterization of Biochemical and Vascular Activities , 2002, Circulation research.

[20]  S. Shyue,et al.  Adenovirus-Mediated Heme Oxygenase-1 Gene Transfer Inhibits the Development of Print , 2001 .

[21]  Lorella Pascolo,et al.  Affinity of Human Serum Albumin for Bilirubin Varies with Albumin Concentration and Buffer Composition , 2001, The Journal of Biological Chemistry.

[22]  Kai Chen,et al.  Neurons Overexpressing Heme Oxygenase‐1 Resist Oxidative Stress‐Mediated Cell Death , 2000, Journal of neurochemistry.

[23]  J Zaky,et al.  Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. , 1999, The Journal of clinical investigation.

[24]  S. Appel,et al.  Protective role of heme oxygenase‐1 in oxidative stress‐induced neuronal injury , 1999, Journal of neuroscience research.

[25]  A. Choi,et al.  Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. , 1999, The Journal of clinical investigation.

[26]  S. Snyder,et al.  Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[28]  M. Dragunow,et al.  The role of neuronal growth factors in neurodegenerative disorders of the human brain , 1998, Brain Research Reviews.

[29]  E. Stopa,et al.  Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease , 1998, Experimental Neurology.

[30]  Wiklund Ra,et al.  First of two parts , 1997 .

[31]  A. Buj-Bello,et al.  Characterization of a multicomponent receptor for GDNF , 1996, Nature.

[32]  B. Rosen,et al.  NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals , 1996, Brain Research.

[33]  E. Stopa,et al.  Expression of heme oxygenase‐1 in the senescent and alzheimer‐diseased brain , 1995, Annals of neurology.

[34]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[35]  P. Escribá,et al.  Regulation of heme oxygenase and metallothionein gene expression by the heme analogs, cobalt-, and tin-protoporphyrin. , 1993, The Journal of biological chemistry.

[36]  C. Olanow.  Oxidation reactions in Parkinson's disease , 1990, Neurology.

[37]  D. Treiman,et al.  The role of benzodiazepines in the management of status epilepticus , 1990, Neurology.

[38]  G. Drummond,et al.  Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Roberts,et al.  Neurochemical changes in rat striatum and substantia nigra following drug administration , 1977, Neurochemical Research.

[40]  H. Marver,et al.  Microsomal heme oxygenase. Characterization of the enzyme. , 1969, The Journal of biological chemistry.

[41]  M. Warin,et al.  UNCORRECTED PROOF , 2000 .

[42]  M. Moore.  Characterization of the enzyme , 1994 .

[43]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.